Taiwan Stock Market Ends Higher as Semiconductor and Energy Shares Lead Gains 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
China to Tighten Crude Steel Output Controls and Export Regulation Through 2030 
Asian Markets Rise as AI Rally Caps 2025, Gold and Silver Hit Record Highs 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
BOJ Minutes Reveal Growing Debate Over Interest Rate Hikes and Inflation Risks 
Tokyo Core Inflation Stays Above BOJ Target, Strengthening Case for Further Rate Hikes 
U.S. Stock Index Futures Steady After S&P 500 Hits Record on Strong Economic Data 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
RBA Signals Possible Interest Rate Hike in 2026 as Inflation Pressures Persist 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Oil Prices Edge Higher as Strong U.S. Growth and Supply Risks Support Market 
Johnson & Johnson is set to pay $230 million to settle a legal case over claims it encouraged and bolstered the opioid addiction predicament in the state of New York. Then again, it was mentioned that despite settling, the company did not acknowledge liability or any wrongdoing in what it was accused of.
What the J&J settlement means
As per BBC News, Johnson & Johnson settlement effectively prevented it from going to trial that is set to start on Tuesday, June 29. The hearing will present a number of opioid manufacturers and distributors as the defendants of the case.
The company said that its agreements with New York State are proportionate with the previous resolution to pay $5 billion to settle the opioid claims. It was added that the arrangement also requires Johnson & Johnson to discontinue the sale of painkillers across the country.
"The opioid epidemic has wreaked havoc on countless communities across New York state and the rest of the nation, leaving millions still addicted to dangerous and deadly opioids," Letitia James, the New York attorney general, said. "Johnson & Johnson helped fuel this fire, but today they're committing to leaving the opioid business - not only in New York but across the entire country."
J&J to take its problematic painkillers off the market
It was mentioned that addiction to opioids, both legal and illegal drugs, has become a serious issue, and this problem is ongoing in countries like the United States. In fact, based on the record of the Centers for Disease Control and Prevention, the country reported almost half a million deaths due to overdoses between the years 1999 and 2019.
While Johnson & Johnson is set to be removed from the trial in New York, it is still facing similar cases in other states such as California. At any rate, the deal with New York also asked the company to stop selling opioids, and it was learned that J&J already did so for some time now.
CNBC reported that Johnson & Johnson confirmed it has ended its opioid business a while ago, even before the settlement with New York. Since 2015, the company stopped marketing opioids in the U.S. and totally withdrew from the business in 2020.
